Polymorphism located between CPT1B and CHKB, and HLA-DRB1*1501-DQB1*0602 haplotype confer susceptibility to CNS hypersomnias (Essential hypersomnia)

PLoS ONE

Volumn 4, Issue 4, 2009, Pages

  Miyagawa, Taku ^a   Honda, Makoto ^b,c   Kawashima, Minae ^a,d   Shimada, Mihoko ^a   Tanaka, Susumu ^b   Honda, Yutaka ^c   Tokunaga, Katsushi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TOKYO METROPOLITAN INSTITUTE OF MEDICAL SCIENCE   (Japan)

^c NEUROPSYCHIATRIC RESEARCH INSTITUTE   (Japan)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARNITINE PALMITOYLTRANSFERASE I; CARNITINE PALMITOYLTRANSFERASE I B; CHECKPOINT KINASE 1; CHECKPOINT KINASE 1 B; HLA DQB1 ANTIGEN; HLA DR ANTIGEN; UNCLASSIFIED DRUG; CARNITINE PALMITOYLTRANSFERASE; CHKB PROTEIN, HUMAN; CHOLINE KINASE; CPT1B PROTEIN, HUMAN; HLA DQ ANTIGEN; HLA DQB1 PROTEIN, HUMAN; HLA-DQB1 PROTEIN, HUMAN; HLA-DRB1 ANTIGEN; MEMBRANE PROTEIN;

ALLELE; ARTICLE; CATAPLEXY; CENTRAL NERVOUS SYSTEM HYPERSOMNIA; CONTROLLED STUDY; DISEASE PREDISPOSITION; ESSENTIAL HYPERSOMNIA; GENE FREQUENCY; GENE INTERACTION; GENETIC MARKER; HAPLOTYPE; HUMAN; HYPERSOMNIA; JAPANESE; MAJOR CLINICAL STUDY; NARCOLEPSY; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; ASIAN; CASE CONTROL STUDY; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; SOMNOLENCE;

ASIAN CONTINENTAL ANCESTRY GROUP; CARNITINE O-PALMITOYLTRANSFERASE; CASE-CONTROL STUDIES; CHOLINE KINASE; DISORDERS OF EXCESSIVE SOMNOLENCE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HAPLOTYPES; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HUMANS; MEMBRANE GLYCOPROTEINS; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 65549133714     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005394     Document Type: Article

References (22)

1. Miyagawa T, Kawashima M, Nishida N, Ohashi J, Kimura R, et al. (2008) Variant between CPT1B and CHKB associated with susceptibility to narcolepsy. Nat Genet 40: 1324-1328.
2. Juji T, Satake M, Honda Y, Doi Y (1984) HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive. Tissue Antigens 24: 316-319.
3. Mignot E, Lin L, Rogers W, Honda Y, Qiu X, et al. (2001) Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 68: 686-699.
4. Langdon N, Welsh KI, van Dam M, Vaughan RW, Parkes D (1984) Genetic markers in narcolepsy. Lancet 2: 1178-1180.
5. Anderson KN, Pilsworth S, Sharples LD, Smith IE, Shneerson JM (2007) Idiopathic hypersomnia: a study of 77 cases. Sleep 30: 1274-1281.
6. Mignot E, Lammers GJ, Ripley B, Okun M, Nevsimalova S, et al. (2002) The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59: 1553-1562.
7. Hong SC, Lin L, Jeong JH, Shin YK, Han JH, et al. (2006) A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness. Sleep 29: 1429-1438.
8. Honda Y, Juji T, Matsuki K, Naohara T, Satake M, et al. (1986) HLA-DR2 and Dw2 in narcolepsy and in other disorders of excessive somnolence without cataplexy. Sleep 9: 133-142.
9. Honda Y, Takahashi Y, Honda M, Watanabe Y, Sato T, et al. (1998) Genetic aspects of narcolepsy Sleep and Sleep Disorders: From Molecule to Behavior; Hayaishi O and Inoue S. Academic Press. pp 341-358.
10. Komada Y, Inoue Y, Mukai J, Shirakawa S, Takahashi K, et al. (2005) Difference in the characteristics of subjective and objective sleepiness between narcolepsy and essential hypersomnia. Psychiatry Clin Neurosci 59: 194-199.
11. McGarry JD, Brown NF (1997) The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. Eur J Biochem 244: 1-14.
12. Yoshida G, Li MX, Horiuchi M, Nakagawa S, Sakata M, et al. (2006) Fasting-induced reduction in locomotor activity and reduced response of orexin neurons in carnitine-deficient mice. Neurosci Res 55: 78-86.
13. Kuwajima M, Fujihara H, Sei H, Umehara A, Sei M, et al. (2007) Reduced Carnitine Level Causes Death from Hypoglycemia: Possible Involvement of Suppression of Hypothalamic Orexin Expression During Weaning Period. Endocr J.
14. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, et al. (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98: 437-451.
15. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, et al. (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 30: 345-354.
16. Tafti M, Petit B, Chollet D, Neidhart E, de Bilbao F, et al. (2003) Deficiency in short-chain fatty acid beta-oxidation affects theta oscillations during sleep. Nat Genet 34: 320-325.
17. Aoyama C, Liao H, Ishidate K (2004) Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 43: 266-281.
18. Kent C (1997) CTP:phosphocholine cytidylyltransferase. Biochim Biophys Acta 1348: 79-90.
19. Zweigner J, Jackowski S, Smith SH, Van Der Merwe M, Weber JR, et al. (2004) Bacterial inhibition of phosphatidylcholine synthesis triggers apoptosis in the brain. J Exp Med 200: 99-106.
20. Fioravanti M, Yanagi M (2005) Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst Rev. pp CD000269.
21. Dixon CE, Ma X, Marion DW (1997) Effects of CDP-choline treatment on neurobehavioral deficits after TBI and on hippocampal and neocortical acetylcholine release. J Neurotrauma 14: 161-169.
22. Nishino S, Mignot E (1997) Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 52: 27-78.